These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1605 related items for PubMed ID: 15721375

  • 1. The liposomal formulation of doxorubicin.
    Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [Abstract] [Full Text] [Related]

  • 2. Liposomal doxorubicin.
    Tardi PG, Boman NL, Cullis PR.
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM, Mumbengegwi DR, Charrois GJ.
    Clin Cancer Res; 2005 May 01; 11(9):3567-73. PubMed ID: 15867261
    [Abstract] [Full Text] [Related]

  • 4. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD, Dougherty G, Harasym TO, Bally MB.
    J Pharmacol Exp Ther; 1997 Mar 01; 280(3):1406-14. PubMed ID: 9067330
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Use of liposomes as injectable-drug delivery systems.
    Ostro MJ, Cullis PR.
    Am J Hosp Pharm; 1989 Aug 01; 46(8):1576-87. PubMed ID: 2672806
    [Abstract] [Full Text] [Related]

  • 9. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ, Masin D, Cullis PR, Bally MB.
    J Pharmacol Exp Ther; 1997 Mar 01; 280(3):1319-27. PubMed ID: 9067319
    [Abstract] [Full Text] [Related]

  • 10. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
    Papagiannaros A, Hatziantoniou S, Dimas K, Papaioannou GT, Demetzos C.
    Biomed Pharmacother; 2006 Jan 01; 60(1):36-42. PubMed ID: 16271845
    [Abstract] [Full Text] [Related]

  • 11. Factors affecting microencapsulation of drugs in liposomes.
    Kulkarni SB, Betageri GV, Singh M.
    J Microencapsul; 1995 Jan 01; 12(3):229-46. PubMed ID: 7650588
    [Abstract] [Full Text] [Related]

  • 12. Liposomal anthracyclines.
    Gabizon AA.
    Hematol Oncol Clin North Am; 1994 Apr 01; 8(2):431-50. PubMed ID: 8040147
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.
    Cancer Chemother Pharmacol; 2010 Nov 01; 66(6):1173-84. PubMed ID: 20661737
    [Abstract] [Full Text] [Related]

  • 14. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
    Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, van Blitterswijk WJ.
    J Pharmacol Exp Ther; 2005 Nov 01; 315(2):704-10. PubMed ID: 16040815
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.
    Cancer Res; 2000 Dec 15; 60(24):6950-7. PubMed ID: 11156395
    [Abstract] [Full Text] [Related]

  • 16. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL, Rauth AM, Bendayan R, Wu XY.
    Eur J Pharm Biopharm; 2007 Mar 15; 65(3):300-8. PubMed ID: 17156986
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ, Lee RJ.
    Anticancer Res; 2003 Mar 15; 23(1A):439-42. PubMed ID: 12680245
    [Abstract] [Full Text] [Related]

  • 19. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB.
    Cancer Res; 1989 Nov 01; 49(21):5922-30. PubMed ID: 2790807
    [Abstract] [Full Text] [Related]

  • 20. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J, Lee A, Lu Y, Lee RJ.
    Int J Pharm; 2007 Jun 07; 337(1-2):329-35. PubMed ID: 17275230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.